CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Status:
Active, not recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The utilization of tamoxifen is considerably high in Indonesia, with about 170,000 tamoxifen
prescriptions filed in 2015. It is metabolized by the enzyme CYP2D6, resulting in its active
metabolite, endoxifen, which has been proven to be effective in the prevention and treatment
of breast cancer.
Studies showed the CYP2D6 gene has more than 100 variants; some of which are linked with
reduced drug activity, while others do not have any pathological implications. The
metabolizer profile of these variants is generally grouped into Ultra-rapid, Normal,
Intermediate, and Poor Metabolizers (UM, NM, IM, and PM, respectively). In our previous study
(NCT04312347), we recruited 200 breast cancer patients who were taking adjusted dose of
tamoxifen daily based on their CYP2D6 phenotype. Although we measured the endoxifen level of
the patients with adjusted treatment, the clinical outcomes of the study are not yet
conclusive.
Phase:
N/A
Details
Lead Sponsor:
Nalagenetics Pte Ltd
Collaborators:
Fakultas Farmasi Universitas Indonesia MRCCC Siloam Hospitals Semanggi SJH Initiatives